JPMorgan Chase & Co. Cuts Humana (NYSE:HUM) Price Target to $256.00

Humana (NYSE:HUM) had its target price decreased by investment analysts at JPMorgan Chase & Co. from $257.00 to $256.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has a “neutral” rating on the insurance provider’s stock. JPMorgan Chase & Co.‘s price objective indicates a potential downside of 0.18% from the stock’s previous close.

A number of other equities analysts have also issued reports on the stock. Morgan Stanley decreased their target price on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 12th. Wells Fargo & Company cut their target price on Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Barclays lifted their price target on Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a research report on Thursday, February 13th. Piper Sandler upped their price objective on Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a report on Wednesday, January 15th. Finally, Bank of America raised Humana from an “underperform” rating to a “neutral” rating and lifted their target price for the stock from $247.00 to $308.00 in a report on Wednesday, November 6th. Nineteen analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $285.68.

Humana Stock Performance

Humana stock traded up $2.63 during midday trading on Tuesday, reaching $256.46. 149,736 shares of the stock traded hands, compared to its average volume of 1,665,199. Humana has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. The firm has a market cap of $30.88 billion, a price-to-earnings ratio of 22.71, a PEG ratio of 2.11 and a beta of 0.56. The firm has a fifty day moving average price of $270.62 and a two-hundred day moving average price of $292.21.

Humana (NYSE:HUM) last issued its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 13.20% and a net margin of 1.18%. On average, equities research analysts forecast that Humana will post 16.11 earnings per share for the current year.

Insider Activity

In other Humana news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.32% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Humana

A number of hedge funds and other institutional investors have recently made changes to their positions in HUM. Creative Financial Designs Inc. ADV lifted its stake in Humana by 244.0% during the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after purchasing an additional 61 shares during the period. FPC Investment Advisory Inc. bought a new position in shares of Humana during the 4th quarter worth approximately $27,000. Centricity Wealth Management LLC bought a new position in shares of Humana during the 4th quarter worth approximately $30,000. Ashton Thomas Securities LLC acquired a new stake in Humana in the 3rd quarter valued at $31,000. Finally, Your Advocates Ltd. LLP grew its position in Humana by 81.8% in the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after acquiring an additional 45 shares during the period. 92.38% of the stock is owned by institutional investors.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.